AI-driven bipolar management market seen growing to $5.2 billion by 2030

A new market report projects rapid expansion for AI-generated personalized bipolar management plans, rising from $1.59 billion in 2025 to $2.02 billion in 2026. The Business Research Company says rising mental health needs, personalized medicine demand and remote monitoring adoption are driving growth, with North America leading and Asia-Pacific set for the fastest gains.

Why it matters: - AI-driven bipolar care is moving from niche innovation to a fast-growing mental health market. - The technology aims to improve treatment matching, relapse detection and therapy adjustments for people living with bipolar disorder. - Faster adoption could change how clinicians use data to manage long-term psychiatric care.

What happened: - The Business Research Company released its Artificial Intelligence (AI)-Driven Personalized Bipolar Management Plans Global Market Report 2026. - The report says the market will rise from $1.59 billion in 2025 to $2.02 billion in 2026, a 26.9% CAGR. - The market is projected to reach $5.2 billion by 2030, growing at a 26.6% CAGR. - The report was published Nov. 3, 2026, from London.

The details: - The report links historical growth to higher bipolar disorder diagnosis rates, wider use of digital mental health platforms, more telepsychiatry access, richer patient data and machine learning advances. - The report defines an AI-generated personalized bipolar management plan as a customized treatment strategy built from medical history, mood changes, lifestyle factors and therapy responses. - The approach is designed to support early relapse detection, tailored treatment recommendations and therapy adjustments. - The report points to growing demand for personalized mental health solutions, AI-enabled clinical decision support, remote monitoring, preventive psychiatry and predictive healthcare analytics as future drivers. - Emerging trends include AI mood tracking, relapse prediction models, electronic health record integration, personalized therapy adjustments and long-term stability tools. - The report says the market is driven in part by rising global mental health disorders and the pressure those conditions place on emotions, cognition, behavior and overall well-being. - The American Psychiatric Association reported in May 2024 that 43% of U.S. adults felt more anxious than the previous year, up from 37% in 2023 and 32% in 2022. - Personalized medicine is another growth driver as treatments increasingly reflect genetics, lifestyle and environmental factors. - The Personalized Medicine Coalition reported in February 2024 that the U.S. Food and Drug Administration approved 26 personalized medicines in 2023, up from 12 in 2022. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated trend analysis. - Download a free sample of the report. - View the full report.

Between the lines: - The forecast suggests AI tools for mental health are gaining traction because they promise more individualized care than traditional one-size-fits-all treatment. - The strongest demand appears tied to rising anxiety and broader mental health awareness, not just bipolar disorder alone. - The emphasis on predictive analytics and remote monitoring suggests buyers want tools that help clinicians act earlier, not just track symptoms.

What's next: - The market’s next phase will likely depend on how quickly providers adopt AI tools inside routine psychiatric care. - Growth will also hinge on integration with electronic health records, clinical workflow fit and evidence that AI-guided plans improve outcomes. - Regional momentum is expected to stay strongest in North America while Asia-Pacific expands fastest.